EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Repurposing metabolic drugs as anti-inflammatory agents

Andrew E Hogan, Cian Davis, Benjamin J Jenkins, Nicholas Jones, Donal O'Shea

Trends in Endocrinology & Metabolism · 2026-04 · 37 (4) · 313-327

DOI: 10.1016/j.tem.2025.07.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2026-04. Verfasst von Andrew E Hogan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland. Electronic address: Andrew.E.Hogan@mu.ie. Hauptthemen laut MEDLINE: Drug Repositioning, Anti-Inflammatory Agents, Inflammation, Metabolic Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Board, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the clinical management of bodyweight and metabolic disease with great success. With their expanded use, it is emerging that the benefits of these drugs extend beyond metabolic improvements into changes in chronic inflammation, potentially independent of those in metabolism. In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond. We highlight the molecular mechanisms via which these drugs exert their anti-inflammatory actions and discuss their potential repurposing as direct anti-inflammatory agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningAnti-Inflammatory AgentsInflammationMetabolic DiseasesHumansSodium-Glucose Transporter 2 InhibitorsAnimalsGlucagon-Like Peptide 1Hypoglycemic Agents

Stichwörter der Autor:innen

SLGT2iglucagon-like peptide-1inflammationobesity

Substanzen

Anti-Inflammatory AgentsSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide 1Hypoglycemic Agents

Autor:innen und Institutionen

  • Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland. Electronic address: Andrew.E.Hogan@mu.ie.
  • St Vincent's University Hospital & University College Dublin, Dublin 4, Ireland.
  • Institute of Life Science, Swansea University Medical School, Swansea, UK.
  • St Vincent's University Hospital & University College Dublin, Dublin 4, Ireland. Electronic address: info@dosheaendo.ie.

Förderung

  • Health Research Board
  • Medical Research Council

Zitieren

APA

Hogan, A. E., Davis, C., Jenkins, B. J., Jones, N., & O'Shea, D. (2026). Repurposing metabolic drugs as anti-inflammatory agents. Trends in Endocrinology & Metabolism, 37(4), 313-327. https://doi.org/10.1016/j.tem.2025.07.003

Vancouver

Hogan AE, Davis C, Jenkins BJ, Jones N, O'Shea D. Repurposing metabolic drugs as anti-inflammatory agents. Trends in Endocrinology & Metabolism. 2026;37(4):313-327. doi:10.1016/j.tem.2025.07.003

BibTeX
@article{Hogan2026,
  author = {Hogan, Andrew E and Davis, Cian and Jenkins, Benjamin J and Jones, Nicholas and O'Shea, Donal},
  title = {Repurposing metabolic drugs as anti-inflammatory agents},
  journal = {Trends in Endocrinology & Metabolism},
  year = {2026},
  volume = {37},
  number = {4},
  pages = {313--327},
  doi = {10.1016/j.tem.2025.07.003}
}
Kostenlos starten →